Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 12/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752419 | 0.89 | MTOR (0.47) | MTORPIK3CA | |
| SCHEMBL751467 | 0.85 | PIK3CA (0.45) | MTORPIK3CAPIK3CG | |
| SCHEMBL2788163 | 0.85 | MTOR (0.57) | MTORPIK3CAADORA2AADORA1CYP3A4 | |
| SCHEMBL754686 | 0.81 | KDM4E (0.44) | MTORPIK3CAKDM4ESMN1; SMN2 | |
| SCHEMBL755161 | 0.81 | MTOR (0.71) | MTORPIK3CAADORA2AADORA1 | |
| SCHEMBL752556 | 0.76 | MTOR (0.72) | MTORPIK3CAADORA2AADORA1CYP3A4 | |
| SCHEMBL754238 | 0.76 | MTOR (0.40) | MTORPIK3CAKDM4ESMN1; SMN2 | |
| SCHEMBL2785811 | 0.76 | PIK3CA (0.48) | MTORPIK3CA | |
| SCHEMBL751459 | 0.74 | PIK3CA (0.42) | MTORPIK3CA | |
| SCHEMBL756258 | 0.73 | MTOR (0.65) | MTORPIK3CAADORA2AADORA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | MTOR 21/4885PIK3CA 1/4885ADORA2A 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.